Literature DB >> 11102464

Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory.

C Leranth1, R H Roth, J D Elsworth, F Naftolin, T L Horvath, D E Redmond.   

Abstract

There are sexual differences in several parameters of the nigrostriatal dopamine neurons, as well as in the progression of diseases associated with this system, e.g., Parkinson's disease and dementia. These differences, as well as direct experimental data in rodents, suggest that gonadal hormones play a role in modulating this system. To determine whether circulating estrogen might have long-term effects by altering the number of dopamine neurons, the density of dopamine neurons was calculated in the compact zone of the substantia nigra of male and intact female short- (10 d) and longer-term (30 d) ovariectomized and short- and longer-term ovariectomized but estrogen-replaced nonhuman primates (African green monkeys). Furthermore, the number of tyrosine hydroxylase-expressing neurons, the total number of all types of neurons, and the volume of the compact zone of the substantia nigra were calculated in 30 d ovariectomized and in 30 d ovariectomized and estrogen-replaced monkeys. Unbiased stereological analyses demonstrated that a 30 d estrogen deprivation results in an apparently permanent loss of >30% of the total number of substantia nigra dopamine cells. Furthermore, the density calculations showed that brief estrogen replacement restores the density of tyrosine hydroxylase-immunoreactive cells after a 10 d, but not after a 30 d, ovariectomy. Moreover, the density of dopamine cells is higher in females than in males. These observations show the essential role of estrogen in maintaining the integrity of the nigral dopamine system, suggest a new treatment strategy for patients with Parkinson's disease and with certain forms of memory-impairing disorders, and provide another rationale for estrogen replacement therapy for postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11102464      PMCID: PMC6773080     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  38 in total

1.  The effect of estrogen replacement on early Parkinson's disease.

Authors:  R Saunders-Pullman; J Gordon-Elliott; M Parides; S Fahn; H R Saunders; S Bressman
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

2.  Restoration of E2F expression rescues vascular endothelial cells from tumor necrosis factor-alpha-induced apoptosis.

Authors:  I Spyridopoulos; N Principe; K L Krasinski; Sh Xu; M Kearney; M Magner; J M Isner; D W Losordo
Journal:  Circulation       Date:  1998 Dec 22-29       Impact factor: 29.690

3.  Activation of human prefrontal cortex during spatial and nonspatial working memory tasks measured by functional MRI.

Authors:  G McCarthy; A Puce; R T Constable; J H Krystal; J C Gore; P Goldman-Rakic
Journal:  Cereb Cortex       Date:  1996 Jul-Aug       Impact factor: 5.357

Review 4.  Estrogen effects on cognition in menopausal women.

Authors:  B B Sherwin
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

5.  Implications of normal brain development for the pathogenesis of schizophrenia.

Authors:  D R Weinberger
Journal:  Arch Gen Psychiatry       Date:  1987-07

6.  Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys.

Authors:  P S Goldman-Rakic; R M Brown
Journal:  Neuroscience       Date:  1981       Impact factor: 3.590

7.  Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect?

Authors:  S M Resnick; E J Metter; A B Zonderman
Journal:  Neurology       Date:  1997-12       Impact factor: 9.910

Review 8.  Neuroprotective effects of estrogens: potential mechanisms of action.

Authors:  P S Green; J W Simpkins
Journal:  Int J Dev Neurosci       Date:  2000 Jul-Aug       Impact factor: 2.457

9.  In vivo gonadotropin-releasing hormone release and serum luteinizing hormone measurements in ovariectomized, estrogen-treated rhesus macaques.

Authors:  J E Levine; R L Norman; P M Gliessman; T T Oyama; D R Bangsberg; H G Spies
Journal:  Endocrinology       Date:  1985-08       Impact factor: 4.736

10.  Sex differences and effects of estrogen on dopamine and DOPAC release from the striatum of male and female CD-1 mice.

Authors:  J L McDermott; B Liu; D E Dluzen
Journal:  Exp Neurol       Date:  1994-02       Impact factor: 5.330

View more
  78 in total

Review 1.  Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.

Authors:  Michel Cyr; Frederic Calon; Marc Morissette; Thérèse Di Paolo
Journal:  J Psychiatry Neurosci       Date:  2002-01       Impact factor: 6.186

Review 2.  Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both?

Authors:  Rachel Saunders-Pullman
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

3.  Risk factors for Parkinson's disease may differ in men and women: an exploratory study.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; J Eric Ahlskog; Walter A Rocca
Journal:  Horm Behav       Date:  2012-06-08       Impact factor: 3.587

4.  Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease.

Authors:  Andrea Tamás; Andrea Lubics; István Lengvári; Dóra Reglodi
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

5.  Oxidative stress and 17-alpha- and 17-beta-estradiol modulate neurofilaments differently.

Authors:  Keith Chiasson; Vicky Lahaie-Collins; Julie Bournival; Benoit Delapierre; Sylvie Gélinas; Maria-Grazia Martinoli
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

Review 6.  Estrogen and adult neurogenesis in the amygdala and hypothalamus.

Authors:  Christie D Fowler; Yan Liu; Zuoxin Wang
Journal:  Brain Res Rev       Date:  2007-07-27

7.  Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease.

Authors:  Jose L Labandeira-Garcia; Jannette Rodriguez-Pallares; Ana I Rodríguez-Perez; Pablo Garrido-Gil; Begoña Villar-Cheda; Rita Valenzuela; Maria J Guerra
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

8.  Sex-specific neuroprotection by inhibition of the Y-chromosome gene, SRY, in experimental Parkinson's disease.

Authors:  Joohyung Lee; Paulo Pinares-Garcia; Hannah Loke; Seungmin Ham; Eric Vilain; Vincent R Harley
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-01       Impact factor: 11.205

9.  Social stress and the polymorphic region of the serotonin reuptake transporter gene modify oestradiol-induced changes on central monoamine concentrations in female rhesus monkeys.

Authors:  J Asher; V Michopoulos; K M Reding; M E Wilson; D Toufexis
Journal:  J Neuroendocrinol       Date:  2013-04       Impact factor: 3.627

Review 10.  The emergence of gonadal hormone influences on dopaminergic function during puberty.

Authors:  Cynthia Kuhn; Misha Johnson; Alex Thomae; Brooke Luo; Sidney A Simon; Guiying Zhou; Q David Walker
Journal:  Horm Behav       Date:  2009-11-10       Impact factor: 3.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.